$CLDX
Celldex Therapeutics, Inc. Stock $cldx

$cldx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914033059 Filed on May 01, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q4
Revenue	$590.0K	$416.0K	$620.0K
YoY Change	508.25%	-82.77%	-83.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.790M	$4.580M	$4.680M
YoY Change	40.47%	45.86%	76.6%
% of Gross Profit
Research & Development	$24.10M	$27.07M	$17.80M
YoY Change	59.71%	92.12%	29.45%
% of Gross Profit
Depreciation & Amortization	$840.0K	$579.0K	$760.0K
YoY Change	15.07%	23.72%	5.56%
% of Gross Profit
Operating Expenses	$29.14M	$27.07M	$22.73M
YoY Change	93.11%	92.12%	36.52%
Operating Profit		-$31.49M
YoY Change		80.96%
Interest Expense	$280.0K	$1.590M	$50.00K
YoY Change	-46.05%	412.9%	-119.23%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$28.27M	-$29.90M	-$22.06M
YoY Change	48.63%	72.53%	31.23%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$28.27M	-$29.90M	-$22.06M
YoY Change	48.63%	72.53%	31.23%
Net Earnings / Revenue	-4791.53%	-7187.5%	-3558.06%
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.688M	-$5.025M	-$3.982M
COMMON SHARES
Basic Shares Outstanding	89.36M shares	89.25M shares	81.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.4M	$274.2M	$303.0M
YoY Change	62.86%	50.36%	260.86%
Cash & Equivalents	$40.80M	$56.90M	$169.4M
Short-Term Investments	$211.6M	$217.3M	$133.6M
Other Short-Term Assets	$2.700M	$2.300M	$1.700M
YoY Change	92.86%	15.0%	54.55%
Inventory
Prepaid Expenses
Receivables	$500.0K	$300.0K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$255.6M	$276.8M	$305.2M
YoY Change	63.4%	50.08%	258.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.60M	$10.22M	$9.973M
YoY Change	44.45%	43.26%	38.42%
Goodwill		$8.965M	$8.965M
YoY Change		0.0%	0.0%
Intangibles		$22.57M	$22.82M
YoY Change		-4.3%	-4.25%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$132.0K	$148.0K
YoY Change	-42.53%	-44.07%	-65.09%
Total Long-Term Assets	$42.00M	$41.88M	$41.91M
YoY Change	5.52%	4.93%	3.66%
TOTAL ASSETS
Total Short-Term Assets	$255.6M	$276.8M	$305.2M
Total Long-Term Assets	$42.00M	$41.88M	$41.91M
Total Assets	$297.6M	$318.7M	$347.1M
YoY Change	51.66%	42.04%	176.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.200M	$3.414M	$2.243M
YoY Change	-42.0%	39.29%	201.07%
Accrued Expenses	$17.90M	$14.97M	$17.18M
YoY Change	80.74%	54.42%	56.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$21.20M	$19.51M	$20.35M
YoY Change	69.56%	6.42%	15.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$4.200M	$7.346M	$6.950M
YoY Change	-36.71%	10.17%	9.69%
Total Long-Term Liabilities	$4.200M	$7.346M	$6.950M
YoY Change	-36.71%	10.17%	9.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.20M	$19.51M	$20.35M
Total Long-Term Liabilities	$4.200M	$7.346M	$6.950M
Total Liabilities	$32.30M	$26.85M	$27.30M
YoY Change	68.77%	-8.74%	-8.29%
SHAREHOLDERS EQUITY
Retained Earnings		-$375.6M	-$345.7M
YoY Change		33.44%	30.88%
Common Stock		$664.8M	$662.8M
YoY Change		40.33%	85.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$265.3M	$291.8M	$319.8M
YoY Change
Total Liabilities & Shareholders Equity	$297.6M	$318.7M	$347.1M
YoY Change	51.66%	42.04%	176.48%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	-$28.27M	-$29.90M	-$22.06M
YoY Change	48.63%	72.53%	31.23%
Depreciation, Depletion And Amortization	$840.0K	$579.0K	$760.0K
YoY Change	15.07%	23.72%	5.56%
Cash From Operating Activities	-$20.85M	-$31.88M	-$14.96M
YoY Change	15.45%	85.35%	12.31%
INVESTING ACTIVITIES
Capital Expenditures	-$890.0K	$195.0K	-$2.320M
YoY Change	17.11%	20.37%	2009.09%
Acquisitions
YoY Change
Other Investing Activities	$5.490M	-$81.13M	-$11.50M
YoY Change	-125.16%	74.77%	159.59%
Cash From Investing Activities	$4.600M	-$81.33M	-$13.82M
YoY Change	-120.37%	74.6%	204.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	160.0K	700.0K	183.6M
YoY Change	-101.76%	-99.39%	837.92%
NET CHANGE
Cash From Operating Activities	-20.85M	-31.88M	-14.96M
Cash From Investing Activities	4.600M	-81.33M	-13.82M
Cash From Financing Activities	160.0K	700.0K	183.6M
Net Change In Cash	-16.09M	-112.5M	154.8M
YoY Change	-67.65%	-321.78%	8950.88%
FREE CASH FLOW
Cash From Operating Activities	-$20.85M	-$31.88M	-$14.96M
Capital Expenditures	-$890.0K	$195.0K	-$2.320M
Free Cash Flow	-$19.96M	-$32.08M	-$12.64M
YoY Change	15.38%	84.74%	-4.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	2000	USD
CY2014Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2013Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2668000	USD
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2689000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-56000	USD
CY2014Q1	us-gaap	Investments And Cash InvestmentsAndCash	274200000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29903000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31875000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5670953	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5088309	shares
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2000	USD
CY2014Q1	cldx	Fair Value Assets Amount Transfers Between Measurement Levels FairValueAssetsAmountTransfersBetweenMeasurementLevels	0	USD
CY2014Q1	cldx	Fair Value Liabilities Amount Transfers Between Measurement Levels FairValueLiabilitiesAmountTransfersBetweenMeasurementLevels	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	133499000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	217241000	USD
CY2013Q4	cldx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	104000	USD
CY2014Q1	cldx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	166000	USD
CY2013Q4	cldx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	22000	USD
CY2014Q1	cldx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	83000	USD
CY2014Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	217324000	USD
CY2014Q1	cldx	Available For Sale Securities Considered To Be Other Than Temporarily Impaired AvailableForSaleSecuritiesConsideredToBeOtherThanTemporarilyImpaired	0	USD
CY2013Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	200000	USD
CY2014Q1	cldx	Period For Which Base Of Operations Must Be Maintained PeriodForWhichBaseOfOperationsMustBeMaintained	P5Y
CY2014Q1	us-gaap	Goodwill Goodwill	8965000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	8965000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5029000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4776000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	400000	USD
CY2014Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	27596000	USD
CY2013Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	27596000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22820000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	22567000	USD
CY2014Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	501000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4661000	USD
CY2014Q1	cldx	Deferred Income From Sale Of Tax Benefits DeferredIncomeFromSaleOfTaxBenefits	2252000	USD
CY2014Q1	us-gaap	Deferred Revenue DeferredRevenue	1059000	USD
CY2014Q1	us-gaap	Other Liabilities OtherLiabilities	8473000	USD
CY2014Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1127000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7346000	USD
CY2013Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	419000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4661000	USD
CY2013Q4	cldx	Deferred Income From Sale Of Tax Benefits DeferredIncomeFromSaleOfTaxBenefits	1630000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	1168000	USD
CY2013Q4	us-gaap	Other Liabilities OtherLiabilities	7878000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	928000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6950000	USD
CY2014Q1	cldx	Value Of Tax Benefits Agreed To Be Sold ValueOfTaxBenefitsAgreedToBeSold	1100000	USD
CY2013Q1	cldx	Value Of Tax Benefits Agreed To Be Sold ValueOfTaxBenefitsAgreedToBeSold	800000	USD
CY2012Q1	cldx	Value Of Tax Benefits Agreed To Be Sold ValueOfTaxBenefitsAgreedToBeSold	800000	USD
CY2011Q1	cldx	Value Of Tax Benefits Agreed To Be Sold ValueOfTaxBenefitsAgreedToBeSold	600000	USD
CY2014Q1	cldx	Value At Which Tax Benefits Sold ValueAtWhichTaxBenefitsSold	1000000	USD
CY2013Q1	cldx	Value At Which Tax Benefits Sold ValueAtWhichTaxBenefitsSold	800000	USD
CY2012Q1	cldx	Value At Which Tax Benefits Sold ValueAtWhichTaxBenefitsSold	700000	USD
CY2011Q1	cldx	Value At Which Tax Benefits Sold ValueAtWhichTaxBenefitsSold	500000	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	13800000	shares
CY2013Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	97000000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1250000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	708000	USD
CY2014Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	3	item
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1717000	USD
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	89357843	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q4	us-gaap	Assets Current AssetsCurrent	305189000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9973000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19507000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	26853000	USD
CY2014Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">(1)  Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics, Inc. (the “Company” or “Celldex”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December 31, 2013, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 3, 2014.  In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company’s financial position and results of operations for the interim periods presented.  The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December 31, 2014.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">At March 31, 2014, the Company had cash, cash equivalents and marketable securities of $274.2 million.  The Company incurred a loss of $29.9 million for the three months ended March 31, 2014.  Net cash used in operations for the three months ended March 31, 2014 was $31.9 million.  The Company believes that the cash, cash equivalents and marketable securities at March 31, 2014 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs.  These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company’s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company’s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company’s economic potential from products under development.</font></p> </div>
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Celldex Therapeutics, Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000744218
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169402000	USD
CY2013Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	489000	USD
CY2013Q4	us-gaap	Assets Assets	347095000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2243000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17179000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20350000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	662717000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-345679000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	319795000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	347095000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	276819000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	291846000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	318699000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2013Q4	us-gaap	Liabilities Liabilities	27300000	USD
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	297000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	297000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89357843	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89357843	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89246832	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89246832	shares
CY2013Q1	cldx	Revenue From Product Development And Licensing Agreements RevenueFromProductDevelopmentAndLicensingAgreements	30000	USD
CY2013Q1	cldx	Revenue From Contracts And Grants RevenueFromContractsAndGrants	50000	USD
CY2013Q1	us-gaap	Royalty Revenue RoyaltyRevenue	2334000	USD
CY2013Q1	us-gaap	Revenues Revenues	2414000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14090000	USD
CY2013Q1	us-gaap	Royalty Expense RoyaltyExpense	2334000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3138000	USD
CY2013Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	253000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	19815000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17401000	USD
CY2013Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	379000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	310000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17332000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	74027000	shares
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	468000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-54000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17388000	USD
CY2014Q1	us-gaap	Revenues Revenues	416000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	31905000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31489000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29901000	USD
CY2013Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	969000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	708000	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	56000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	60000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1234000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-188000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	206000	USD
CY2013Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	516000	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7394000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-17200000	USD
CY2013Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	53809000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	162000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-46577000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	114187000	USD
CY2013Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1660000	USD
CY2013Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1323000	USD
CY2013Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	15000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	114509000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-2000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	50730000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-81328000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	702000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-112500000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56902000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75627000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24897000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89270000	shares
CY2014Q1	us-gaap	Interest Receivable InterestReceivable	1300000	USD
CY2014Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	305000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2288000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10216000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	132000	USD
CY2014Q1	us-gaap	Assets Assets	318699000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3414000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14966000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	89000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	664669000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375582000	USD
CY2014Q1	cldx	Revenue From Product Development And Licensing Agreements RevenueFromProductDevelopmentAndLicensingAgreements	35000	USD
CY2014Q1	cldx	Revenue From Contracts And Grants RevenueFromContractsAndGrants	381000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27070000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4582000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	253000	USD
CY2014Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1586000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	579000	USD
CY2014Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2129000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1250000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-184000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1051000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-16000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1669000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	595000	USD
CY2014Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	112416000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	195000	USD
CY2014Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	702000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1000	USD
CY2013Q4	us-gaap	Interest Receivable InterestReceivable	900000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	31283000	USD

Files In Submission

Name	View Source	Status
0001104659-14-033059-index-headers.html	Edgar Link	pending
0001104659-14-033059-index.html	Edgar Link	pending
0001104659-14-033059.txt	Edgar Link	pending
0001104659-14-033059-xbrl.zip	Edgar Link	pending
a14-8947_110q.htm	Edgar Link	pending
a14-8947_1ex31d1.htm	Edgar Link	pending
a14-8947_1ex31d2.htm	Edgar Link	pending
a14-8947_1ex32d1.htm	Edgar Link	pending
cldx-20140331.xml	Edgar Link	completed
cldx-20140331.xsd	Edgar Link	pending
cldx-20140331_cal.xml	Edgar Link	unprocessable
cldx-20140331_def.xml	Edgar Link	unprocessable
cldx-20140331_lab.xml	Edgar Link	unprocessable
cldx-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLDX
Celldex Therapeutics, Inc. Stock $cldx

2014 Q2 Form 10-Q Financial Statement

#000110465914033059 Filed on May 01, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLDX Celldex Therapeutics, Inc. Stock $cldx

2014 Q2 Form 10-Q Financial Statement

#000110465914033059 Filed on May 01, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLDX
Celldex Therapeutics, Inc. Stock $cldx